OncoOne

OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF). The Company is focused on developing multiple proprietary drug modalities to leverage oxMIF's potential as a target for systemic treatment of colorectal, ovarian and lung cancers, as well as for chronic inflammatory diseases. Equipped with a successful track-record in early-stage drug development, as well as a deep understanding of the target itself, OncoOne's leadership will advance a pipeline based on oxMIF's promise in oncology and other disease areas. www.oncoone.com